JBI 295
Alternative Names: JBI-295Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Jubilant Biosys
- Class Antineoplastics; Small molecules
- Mechanism of Action HDAC6 protein inhibitors; HDAC8 protein inhibitors; Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Malignant melanoma
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in India (PO)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Malignant-melanoma in India (PO)